AstraZeneca: Alexion to Discontinue Ultomiris Phase 3 ALS Trial
20 August 2021 - 8:46AM
Dow Jones News
By Ian Walker
AstraZeneca PLC said Friday that Alexion is discontinuing the
Phase 3 trial of Ultomiris in amyotrophic lateral sclerosis
following a recommendation by the Independent Data Monitoring
Committee.
The drug giant said that the committee recommended the trial
stop due to lack of efficacy, adding that no new safety findings
were observed.
Amyotrophic lateral sclerosis is a rare disease that affects
motor neurons in the brain and spinal cord.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
August 20, 2021 02:40 ET (06:40 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
